Evelo Biosciences to Participate in Cowen 42nd Annual Health Care Conference
March 02 2022 - 07:00AM
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage
biotechnology company developing SINTAX™ medicines as a new
modality of orally delivered treatments for inflammatory disease,
today announced that Simba Gill, Ph.D., Chief Executive Officer of
Evelo, will participate in a panel discussion titled
“GI/Microbiome” at the Cowen 42nd Annual Health Care Conference on
Wednesday, March 9th, 2022 at 10:30 a.m. ET.
A live audio webcast of the panel will be available under “News
and Events” in the Investors section of Evelo's website at
http://ir.evelobio.com. A replay of the webcast will be available
for approximately 30 days following the presentation.
About Evelo BiosciencesEvelo
Biosciences is a clinical stage biotechnology company
developing orally delivered product candidates that are designed to
act on the small intestinal axis, SINTAX™, with systemic
therapeutic effects. SINTAX plays a central role in governing the
immune, metabolic, and neurological systems. The Company’s first
product candidates are pharmaceutical preparations of single
strains of microbes selected for their potential to offer defined
pharmacological properties. Evelo’s therapies have the potential to
be effective, safe, and affordable medicines to improve the lives
of people with inflammatory diseases.
Evelo currently has three product candidates in development:
EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory
diseases. Evelo is advancing additional product candidates in other
disease areas.
For more information, please
visit www.evelobio.com and engage with Evelo
on LinkedIn.
Contacts
Investors:Kendra Sweeney,
239-877-7474ksweeney@evelobio.com
Media:Jessica Cotrone,
978-760-5622jcotrone@evelobio.com
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Mar 2023 to Mar 2024